Melanotan (MT)-II acetate
Based on 1 publication(s) in Google Scholar
Melanotan (MT)-II acetate is a melanocortin receptor agonist. Melanotan (MT)-II acetate activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II acetate reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II acetate improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II acetate induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II acetate increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II acetate can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction.
For research use only. We do not sell to patients.
- CAS No.: 1036322-26-5
- Formula: C52H73N15O11
- Molecular Weight:1084.23
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Melanotan (MT)-II acetate
More
Customer Validation & Images
-
In Vivo Efficacy Study
Biological Activity
|
MC3R |
MC4R |
Melanotan (MT)-II (2.5 μg per day; intracerebroventricular injection; continuous infusion; 7 days) acetate rescues social ability deficits in adult male maternal immune activation (MIA) mice, increasing the social ability index score from 3.1 to 26.3[2].
Melanotan (MT)-II (0.1-1 nM, microinjected bilaterally into the nucleus accumbens) acetate significantly reduces 24-hour food intake in fasted C57BL/6J mice, produces a significant anorectic effect, and decreases feeding responses in ad libitum-fed mice[3].
Melanotan (MT)-II (0.1-1 mg/kg, intravenous injection) acetate significantly enhances the overall erectile activity in conscious rats and shortens the latency of the first erectile event in anesthetized rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Danio rerio, longfin phenotype (3-5 months old, ~50:50 male to female ratio, high-fat diet-induced model)[1]
-
Dosage:20 μM
-
Administration:percutaneous immersion; two days
-
Result:Reversed the significant reduction in time spent in the red (reinforced) arm of the Y-maze (HF + MT-II group spent significantly more time than untreated HF group, matching control group levels).
Reversed the HF diet-induced increase in time spent in the Y-maze start arm (a marker of anxiety).
Restored total object exploration time in the one-trial memory test to control group levels.
-
Animal Model:C57BL/6J (4-6 month-old male; maternal immune activation model)[2]
-
Dosage:2.5 μg/day
-
Administration:i.c.v.; continuous infusion; 7 days
-
Result:Increased sociability index score significantly from 3.1 to 26.3.
Did not produce a significant change in social novelty scores.
-
Animal Model:C57BL/6J (male, 2-3 months old, average body weight ~22 g, food-deprived for ~16 hours to induce food-motivated state)[3]
-
Dosage:0.1, 0.3, 1 nM/side
-
Administration:bilateral microinjection into nucleus accumbens; single dose
-
Result:Significantly decreased food intake at 1, 2, and 4 hours post-injection compared to saline.
Significantly decreased food intake at 24 hours post-injection only at 0.3 nmol/side dose compared to saline.
Showed a significant main effect of drug, time, and drug-time interaction.
-
Animal Model:Sprague-Dawley (male, 225-250 g, telemetric intracavernosal pressure monitoring model)[4]
-
Dosage:0.1 mg/kg; 0.3 mg/kg; 1 mg/kg
-
Administration:i.v.
-
Result:Induced at least one penile erection in 4 out of 5 rats, with a mean 1.6 erections, mean latency to first erection of 2812 s, mean ICPmax of ~360 mmHg, mean AUC of ~2100 mmHg.s, and mean SUM AUC of ~3000 mmHg.s at 0.1 mg/kg.
Induced at least one penile erection in 4 out of 6 rats, with a mean 1.8 erections, mean latency to first erection of 2616 s, mean ICPmax of 472 mmHg, mean AUC of ~2200 mmHg.s, and mean SUM AUC of ~4000 mmHg.s at 0.3 mg/kg.
Induced at least one penile erection in 6 out of 8 rats, with a mean 4.8 erections, mean latency to first erection of 1780 s, mean ICPmax of 548 mmHg, mean AUC of ~2300 mmHg.s, and mean SUM AUC of 10653 mmHg.s at 1 mg/kg.
Chemical Information
-
CAS No. 1036322-26-5
-
Molecular Weight 1084.23
-
Formula C52H73N15O11
-
Sequence
Ac-{Nle}-Asp-His-{d-Phe}-Arg-Trp-Lys-NH2, (2→7)-lactam
-
Sequence Shortening
Ac-{Nle}-DH-{d-Phe}-RWK-NH2, (2→7)-lactam
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
Tak1 licenses mitochondrial transfer from astrocytes to POMC neurons to maintain glucose and cholesterol homeostasis. [Abstract]2024 Nov 19;43(12):114983. PMID: 39565693
Melanotan (MT)-II acetate purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Nov 19;43(12):114983. [Abstract]
Artificial cerebrospinal fluid (aCSF) and Melanotan (MT)-II (MTII, 1 μg (in 0.5 μL of aCSF); i.c.v.), an MC3/4R agonist, were administered into the third ventricle of male adult mice. GTT was then performed, and the AUC of the GTT was calculated. Melanotan (MT)-II (MTII, 1 μg (in 0.5 μL of aCSF); i.c.v.), an MC3/4R agonist, largely reversed the impaired glucose tolerance caused by astrocytic Tak1 ablation in GTKO mice. i.c.v., intracerebroventricularly; NS, not significant.
Purity & Documentation
References
[1]. Wekwejt P, et al. Melanotan-II reverses memory impairment induced by a short-term HF diet. Biomed Pharmacother. 2023;165:115129. [Content Brief]
[2]. Minakova E, et al. Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PLoS One. 2019;14(1):e0210389. Published 2019 Jan 10. [Content Brief]
[3]. Eliason NL, et al. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022;96:102289. [Content Brief]
[4]. Giuliano F, et al. The use of telemetry technology to test the proerectile effect of melanotan-II (MT-II) in conscious rats. Eur Urol. 2005 Jul;48(1):145-51; discussion 151-2. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Melanotan (MT)-II acetate Related Classifications
HY-P0267A Related Classifications
Powered by Bioz